Racura Oncology's seamless phase 2b/3 Emili trial for recurrent or refractory acute myeloid leukemia received initial center approval.

Zhitongcaijing · 1d ago
Racura Oncology's seamless phase 2b/3 Emili trial for recurrent or refractory acute myeloid leukemia received initial center approval.